Vaxart shareholders rejected the company's non-binding advisory vote on executive compensation at its 2026 annual meeting, even as they re-elected the full board and ratified the auditor. CEO Steven Lo said the company is not planning a reverse stock split right now and has no current plan to call a special meeting on the issue, preferring to focus on executing its strategy and allowing the stock price to improve organically. Management highlighted progress on Vaxart's COVID-19 and norovirus programs, including encouraging safety data from the COVID study and ongoing talks for a potential norovirus partnership. The company said its cash runway extends through the second quarter of 2027 and it continues seeking non-dilutive funding.
Vaxart IncShareholders rejected say-on-pay proposal, but board re-elected and auditor ratified; CEO ruled out reverse split, focusing on organic improvement.